2,6-dimethyl-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidine | 66521-81-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: 2,6-dimethyl-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidine
• 英文别名: 2,6-Dimethyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine；2,6-dimethyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine
• CAS: 66521-81-1
• 化学式: C₉H₁₃N₃
• mdl: MFCD24843109
• 分子量: 163.222
• InChiKey: ZSYMUDINLXUXEX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.555
• 拓扑面积：
  29
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  (E)-3-((dimethylamino)methylene)-1-methylpiperidin-4-one 以71%的产率得到
  参考文献：
  名称：

  BENNETT G. B.; MASON R. B.; ALDEN L. J.; ROACH J. B., J. MED. CHEM., 1978, 21, NO 7, 623-628

  摘要：

  DOI：

文献信息

• Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
  申请人：Gao Yang

  公开号：US20070232591A1

  公开（公告）日：2007-10-04

  Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues of the Formula: are provided, in which variables are as described herein. Such compounds may be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) and other disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).

  提供了式子中描述的Piperazinyl oxoalkyl tetrahydroisoquinolines和相关类似物，其中变量如此处所述。这些化合物可用于调节体内或体外的组胺H3受体的配体结合，并且在治疗人类、驯养伴侣动物和家畜动物的各种中枢神经系统（CNS）和其他疾病方面特别有用。此处提供的化合物可以单独或与一种或多种其他CNS药物联合使用，以增强其他CNS药物的效果。提供了用于治疗此类疾病的制药组合物和方法，以及用于检测组胺H3受体（例如受体定位研究）的配体的方法。
• PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES
  申请人：Gao Yang

  公开号：US20110082130A1

  公开（公告）日：2011-04-07

  Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues of the Formula: are provided, in which variables are as described herein. Such compounds may be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) and other disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).

  本文提供了公式中所述的哌嗪氧代烷基四氢异喹啉及其相关类似物，其中变量如本文所述。这些化合物可用于在体内或体外调节组胺H3受体的配体结合，并且在治疗人类、驯养宠物和家畜动物的各种中枢神经系统（CNS）和其他疾病方面特别有用。本文提供的化合物可以单独或与一个或多个其他CNS药物联合使用，以增强其他CNS药物的效果。还提供了用于治疗此类疾病的制药组合物和方法，以及用于检测组胺H3受体（例如受体定位研究）的配体的方法。
• ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE
  申请人：Medshine Discovery Inc.

  公开号：EP3252059A1

  公开（公告）日：2017-12-06

  Disclosed is a substituted nitroimidazole derivative, which is mainly used for treating related diseases caused by mycobacterial infections, such as Mycobacterium tuberculosis, especially being suitable for diseases caused by resistant Mycobacterium tuberculosis.

  本发明公开了一种取代的硝基咪唑衍生物，主要用于治疗结核分枝杆菌等分枝杆菌感染引起的相关疾病，尤其适用于耐药结核分枝杆菌引起的疾病。
• Anti-pulmonary tuberculosis nitroimidazole derivative
  申请人：MEDSHINE DISCOVERY INC.

  公开号：US10227362B2

  公开（公告）日：2019-03-12

  Disclosed is a substituted nitroimidazole derivative, which is mainly used for treating related diseases caused by mycobacterial infections, such as Mycobacterium tuberculosis, especially being suitable for diseases caused by resistant Mycobacterium tuberculosis.

  本发明公开了一种取代的硝基咪唑衍生物，主要用于治疗结核分枝杆菌等分枝杆菌感染引起的相关疾病，尤其适用于耐药结核分枝杆菌引起的疾病。
• [EN] ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE<br/>[FR] DÉRIVÉ DE NITROIMIDAZOLE ANTI-TUBERCULOSE PULMONAIRE<br/>[ZH] 抗肺结核病的硝基咪唑衍生物
  申请人：MEDSHINE DISCOVERY INC

  公开号：WO2016119706A1

  公开（公告）日：2016-08-04

  本发明公开了一种取代硝基咪唑类衍生物，其主要用于治疗由分支杆菌感染引起的相关疾病，如结核分枝杆菌，尤其适用于耐药性结核分支杆菌引起的疾病。